A detailed history of Lindbrook Capital, LLC transactions in Erasca, Inc. stock. As of the latest transaction made, Lindbrook Capital, LLC holds 912 shares of ERAS stock, worth $2,489. This represents 0.0% of its overall portfolio holdings.

Number of Shares
912
Previous 745 22.42%
Holding current value
$2,489
Previous $1,000 100.0%
% of portfolio
0.0%
Previous 0.0%

Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 01, 2024

BUY
$2.17 - $3.28 $362 - $547
167 Added 22.42%
912 $2,000
Q2 2024

Jul 31, 2024

BUY
$1.79 - $2.63 $1,333 - $1,959
745 New
745 $1,000
Q1 2024

Apr 25, 2024

SELL
$1.67 - $2.55 $2,788 - $4,258
-1,670 Closed
0 $0
Q4 2023

Jan 31, 2024

BUY
$1.67 - $2.49 $1,037 - $1,546
621 Added 59.2%
1,670 $3,000
Q3 2023

Oct 25, 2023

SELL
$1.97 - $2.91 $602 - $890
-306 Reduced 22.58%
1,049 $2,000
Q2 2023

Jul 28, 2023

SELL
$2.57 - $3.3 $1,148 - $1,475
-447 Reduced 24.81%
1,355 $3,000
Q1 2023

Apr 26, 2023

BUY
$2.74 - $4.44 $4,937 - $8,000
1,802 New
1,802 $5,000

Others Institutions Holding ERAS

About Erasca, Inc.


  • Ticker ERAS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 122,147,000
  • Market Cap $333M
  • Description
  • Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; ...
More about ERAS
Track This Portfolio

Track Lindbrook Capital, LLC Portfolio

Follow Lindbrook Capital, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Lindbrook Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Lindbrook Capital, LLC with notifications on news.